Filtered By:
Education: Study
Procedure: Percutaneous Coronary Intervention
This page shows you your search results in order of date. This is page number 18.
Order by Relevance | Date
Total 2305 results found since Jan 2013.
Effects of Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting on Clinical Outcomes in Patients with Reduced Ejection Fraction Heart Failure and Coronary Heart Disease: A Meta-Analysis
CONCLUSIONS: The mortality rates of PCI and CABG were similar in patients with CHD complicated with HFrEF. Compared with PCI, CABG had a lower incidence of MACE, MI, HF, and revascularization, and a higher incidence of stroke or TIA.PMID:36856505 | DOI:10.1532/hsf.5169
Source: The Heart Surgery Forum - March 1, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Zi-Xiang Yu Ju Yan Ming-Yuan Wang Rong Chen Jun-Yi Luo Xiao-Mei Li Xiang Xie Yi-Tong Ma Source Type: research
Utilization of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention
ConclusionsThe utilization of TAT following PCI among high-stroke risk AF patients steadily increased from 2011 to 2020, reaching 65.4% by the end of the study period. However, in 2020, a significant proportion of 29.4% of patients still received DAPT, indicating that many AF patients undergoing PCI did not receive adequate antithrombotic therapy.
Source: European Journal of Clinical Pharmacology - February 24, 2023 Category: Drugs & Pharmacology Source Type: research
Antithrombotic therapy and bleeding risk in the era of aggressive lipid-lowering: current evidence, clinical implications, and future perspectives
Chin Med J (Engl). 2023 Feb 21. doi: 10.1097/CM9.0000000000002057. Online ahead of print.ABSTRACTThe clinical efficacy of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in reducing major cardiovascular adverse events related to atherosclerotic cardiovascular disease (ASCVD) has been well established in recent large randomized outcome trials. Although the cardiovascular and all-cause mortality benefit of PCSK9i remains inconclusive, current cholesterol management guidelines have been modified toward more aggressive goals for lowering low-density lipoprotein cholesterol (LDL-C). Consequently, the emerging ...
Source: Chinese Medical Journal - February 22, 2023 Category: General Medicine Authors: Xin Zhou Ziping Li Hangkuan Liu Yongle Li Dong Zhao Qing Yang Source Type: research
Prognostic value of gut microbiota-derived metabolites in patients with ST-segment elevation myocardial infarction
CONCLUSIONS: Higher plasma PAGln, IS, DCA, TML, and TMAO levels are independently associated with MACEs suggesting that these metabolites may be useful markers for prognosis in patients with STEMI.PMID:36811471 | DOI:10.1016/j.ajcnut.2022.12.013
Source: Am J Clin Nutr - February 22, 2023 Category: Nutrition Authors: Suhong Zhao Yanan Tian Shanjie Wang Fan Yang Junyan Xu Zhifeng Qin Xinxin Liu Muhua Cao Peng Zhao Guohua Zhang Zhuozhong Wang Yiying Zhang Yidan Wang Kaiyang Lin Shaohong Fang Zhao Wang Tianshu Han Maoyi Tian Huiyong Yin Jinwei Tian Bo Yu Source Type: research
